Literature DB >> 24820079

Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii.

Sarunyou Chusri1, Virasakdi Chongsuvivatwong2, Jesabel I Rivera3, Kachornsakdi Silpapojakul4, Kamonnut Singkhamanan5, Edward McNeil2, Yohei Doi6.   

Abstract

The role of Acinetobacter nosocomialis and Acinetobacter pittii, which belong to the A. calcoaceticus-A. baumannii complex, in hospital-acquired infections is increasingly recognized. Here we describe a retrospective cohort study of hospital-acquired A. calcoaceticus-A. baumannii complex infections at a university hospital in Thailand. A total of 222 unique cases were identified between January 2010 and December 2011. The genomospecies of the A. calcoaceticus-A. baumannii complex isolates were classified as follows: A. baumannii, 197 (89%); A. nosocomialis, 18 (8%); and A. pittii, 7 (3%). All A. nosocomialis and A. pittii isolates were susceptible to imipenem and meropenem. The patients infected with A. nosocomialis and A. pittii had lower 30-day mortality than those infected with carbapenem-susceptible A. baumannii (P = 0.025) and carbapenem-resistant A. baumannii (P = 0.013). The factors influencing 30-day mortality were infection with non-baumannii A. calcoaceticus-A. baumannii complex (hazard ratio [HR], 0.12; 95% confidence interval [CI], 0.03 to 0.51; P = 0.004), infection with carbapenem-resistant A. baumannii (HR, 1.57; 95% CI, 0.89 to 2.79; P = 0.105), appropriate empirical antimicrobial therapy (HR, 0.38; 95% CI, 0.23 to 0.61; P < 0.001), and higher acute physiology and chronic health evaluation II (APACHE II) score (HR, 1.15; 95% CI, 1.10 to 1.19; P < 0.001). In Galleria mellonella assays, the survival rates were significantly higher for the larvae infected with A. nosocomialis or A. pittii than for those infected with either carbapenem-susceptible A. baumannii or carbapenem-resistant A. baumannii, but no differences in survival rates were observed between carbapenem-susceptible A. baumannii and carbapenem-resistant A. baumannii. These findings suggest intrinsic differences in virulence between non-baumannii A. calcoaceticus-A. baumannii complex species and A. baumannii but not between carbapenem-susceptible and resistant A. baumannii.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24820079      PMCID: PMC4068534          DOI: 10.1128/AAC.02992-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

Review 2.  Acinetobacter infection.

Authors:  L Silvia Munoz-Price; Robert A Weinstein
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

3.  Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

4.  Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.

Authors:  Shalini Yapa; Jian Li; Kashyap Patel; John W Wilson; Michael J Dooley; Johnson George; Denise Clark; Susan Poole; Elyssa Williams; Christopher J H Porter; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

5.  Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp.

Authors:  Neil Woodford; Matthew J Ellington; Juliana M Coelho; Jane F Turton; M Elaina Ward; Susan Brown; Sebastian G B Amyes; David M Livermore
Journal:  Int J Antimicrob Agents       Date:  2006-03-24       Impact factor: 5.283

6.  Reliability of phenotypic tests for identification of Acinetobacter species.

Authors:  P Gerner-Smidt; I Tjernberg; J Ursing
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

Review 7.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 8.  Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.

Authors:  Lisa L Maragakis; Trish M Perl
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

9.  Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species.

Authors:  Bernard La Scola; Vijay A K B Gundi; Atieh Khamis; Didier Raoult
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics.

Authors:  Anton Y Peleg; Sebastian Jara; Divya Monga; George M Eliopoulos; Robert C Moellering; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

View more
  40 in total

1.  First Report of the Carbapenemase Gene blaOXA-499 in Acinetobacter pittii.

Authors:  Roshan D'Souza; Naina Adren Pinto; Paul G Higgins; Insik Hwang; Dongeun Yong; Jongrak Choi; Kyoungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Authors:  Sarah M McLeod; Samir H Moussa; Meredith A Hackel; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  A Prospective Study of Acinetobacter baumannii Complex Isolates and Colistin Susceptibility Monitoring by Mass Spectrometry of Microbial Membrane Glycolipids.

Authors:  Lisa M Leung; Christi L McElheny; Francesca M Gardner; Courtney E Chandler; Sarah L Bowler; Roberta T Mettus; Caressa N Spychala; Erin L Fowler; Belita N A Opene; Robert A Myers; David R Goodlett; Yohei Doi; Robert K Ernst
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

Review 4.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Multicenter evaluation of the VITEK MS matrix-assisted laser desorption/ionization-time of flight mass spectrometry system for identification of bacteria, including Brucella, and yeasts.

Authors:  Victoria Girard; Valérie Monnin; Delphine Giraud; Sophie Polsinelli; Marion Caillé; Gary W Procop; Marion Tuohy; Deborah Wilson; Sandra S Richter; Katalin Kiss; Kimberly Clem; Nicholas Tolli; Laurence Bridon; Constance Bradford; Sara Blamey; Jay Li; David H Pincus
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-10       Impact factor: 3.267

6.  Outer membrane Protein A plays a role in pathogenesis of Acinetobacter nosocomialis.

Authors:  Sang Woo Kim; Man Hwan Oh; So Hyun Jun; Hyejin Jeon; Seung Il Kim; Kwangho Kim; Yoo Chul Lee; Je Chul Lee
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

Review 7.  Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.

Authors:  David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

8.  Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance.

Authors:  Margaret A Fitzpatrick; Egon Ozer; Maureen K Bolon; Alan R Hauser
Journal:  J Infect       Date:  2014-09-19       Impact factor: 6.072

Review 9.  Uncovering the mechanisms of Acinetobacter baumannii virulence.

Authors:  Christian M Harding; Seth W Hennon; Mario F Feldman
Journal:  Nat Rev Microbiol       Date:  2017-12-18       Impact factor: 60.633

10.  Defining the interaction of the protease CpaA with its type II secretion chaperone CpaB and its contribution to virulence in Acinetobacter species.

Authors:  Rachel L Kinsella; Juvenal Lopez; Lauren D Palmer; Nichole D Salinas; Eric P Skaar; Niraj H Tolia; Mario F Feldman
Journal:  J Biol Chem       Date:  2017-10-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.